views

EKF Diagnostics – argues remains positive of capacity expansion “significant benefit”... but not sufficiently for the CEO to remain in situ?!

EKF Diagnostics (EKF) has issued a “trading update” – it stating “reflecting strong growth in the core established business… also gives a progress update on the expansion of the Life Sciences enzyme fermentation business and on the transition of Contract Manufacturing & Laboratory Testing into non-COVID revenues”. So what of a share price response to currently 32.6p, approaching 17% lower?

NEWSFLOW

#EKF Diagnostics – “transition to non-COVID revenues… taking longer than originally anticipated”

NEWSFLOW

#EKF Diagnostics – 2021 ahead of expectations, though covid-related benefit

NEWSFLOW

#EKF Diagnostics – trading “materially ahead of management expectations” & confident will continue for FY21

views

Here's a Promising Company that's Already Involved in the Covid Testing Process

Hello Share Takers. There are a few companies that are already growing because of the Covid outbreak. I’m not talking about all those hopefuls who are chasing tests and making sanitisers. But a few that are already making a solid contribution to fighting the pandemic. One such outfit is EKF Diagnostics (EKF)...

NEWSFLOW

#EKF Diagnostics – “trading in October is expected to demonstrate continued and strong overall growth”

NEWSFLOW

#EKF Diagnostics says Q2 trading strong, FY EBITDA will beat forecasts, cash generation strong

NEWSFLOW

#EKF Diagnostics – Q3 trading “materially higher than budget”, confident of exceeding high end of current FY forecasts

NEWSFLOW

EKF Diagnostics (#EKF) - bookbuild for underwritten placing, 42m shares

NEWSFLOW

EKF (#EKF) warns 2015 writedowns now to be up to £60m - says 2016 will be better